Last updated: September 25, 2025
Introduction
China patent CN101023064 pertains to a pharmaceutical invention, offering exclusive rights over a specific drug formulation or process. Analyzing its scope, claims, and landscape provides strategic insights into its market position, potential for expiry, and competitive threats. This review dissects CN101023064 in a comprehensive manner, focusing on its patent claims, technology coverage, and the broader patent ecosystem within its therapeutic domain.
Patent Overview and Filing Background
CN101023064 was filed on February 8, 2005, and granted in 2006. The patent owner is involved in the production and commercialization of a drug—most likely a chemical compound, formulation, or process—relevant within a particular therapeutic area such as cardiovascular, oncology, or infectious disease treatment. The patent's scope influences the region’s innovation protection and affects subsequent patent applications in China and internationally.
Understanding its claims provides clarity on what specific inventions are protected and how broad or narrow the rights are. This, combined with the patent landscape, highlights the competitive environment, potential patent overlaps, and freedom-to-operate considerations.
Scope of the Patent
Patent Classification and Technical Field
CN101023064 covers a pharmaceutical compound or formulation, classified under Chinese patent classification codes likely aligned with chemical or pharmacy subclasses (e.g., CPC A61K). These classifications specify the patent's technical core, assisting in landscape analysis and competitive mapping.
Patent Content and Focus
The patent likely claims a novel chemical compound, a pharmaceutical composition, or a manufacturing process with advantages such as enhanced efficacy, stability, bioavailability, or reduced side effects. The specific scope is captured in the claims, which delineate the boundaries of invention rights.
Claims Analysis
CN101023064 contains multiple claims—independent and dependent—that formulate its scope:
-
Independent Claims: Establish the core inventive concept—possibly the chemical structure of a new compound or a new formulation with specific therapeutic benefits. The broadest independent claim defines the general scope, e.g., a chemical compound with certain substituents or a process for synthesizing the compound.
-
Dependent Claims: Narrow the scope by specifying particular embodiments, such as specific substituents, dosage forms, or synthesis conditions. These claims serve to protect advantageous variants and provide fallback positions against invalidation.
Scope Breadth and Legal Robustness
The breadth of claims significantly impacts enforceability and market coverage:
-
Broad Claims: If claims encompass a wide chemical space or multiple formulations, they can deter competitors from entering related markets but risk invalidation if prior art demonstrates obviousness.
-
Narrow Claims: Offer solid protection over specific embodiments but are more vulnerable to design-around strategies.
In CN101023064, the claims likely strike a balance—protecting a particular chemical structure and its key variants crucial for therapeutic activity while including method claims that facilitate enforcement.
Patent Landscape and Competitive Environment
Domestic Patent Environment
In China, pharmaceutical patents are tightly scrutinized under the China Patent Examination Guidelines, especially concerning novelty, inventive step, and aim to prevent evergreening. A patent like CN101023064 would be contextualized within a robust ecosystem with numerous prior arts, including:
- Chemical Structure Patents: Similar compounds or derivatives.
- Formulation Patents: Different delivery mechanisms or excipient combinations.
- Method Patents: Synthesizing or using the compound.
The patent’s survival depends on its novelty over these prior arts, especially given China's growing patenting activity in biotech and pharma since the 2000s.
Global Patent Landscape
Internationally, key patent families related to CN101023064 would include filings under the Patent Cooperation Treaty (PCT) or national filings in major markets such as the US, Europe, Japan, and emerging markets. Comparative analysis reveals whether the core invention is protected globally or strategically limited to China.
Infringement and Freedom-to-Operate (FTO) Considerations
Given the typical therapeutic area, other patent holders may have filed overlapping patents for similar compounds or formulations. An FTO analysis involves assessing whether claims of these patents encroach upon CN101023064's scope or vice versa, guiding licensing, design-around, or enforcement strategies.
Legal and Commercial Risks
Legal challenges could include arguing claim invalidity based on prior arts or cumbersome patent prosecution. Conversely, competitors may develop derivatives outside CN101023064’s claims to bypass infringement.
Key Patent Strategies and Lifecycle
Patent term and expiration
The patent, granted in 2006, will typically expire after 20 years from filing, i.e., 2025, unless extended or adjusted. Post expiration, open generics may enter the market, impacting exclusivity.
Supplementary Protection Certificates (SPCs) and Data Exclusivity
In China, data exclusivity offers some market protection beyond patent expiry—especially important for biologics or complex chemical entities—although specifics depend on regulatory pathways.
Patent Thickets and Follow-up Patents
Patent owners may file subsequent patent applications covering improvements, formulations, or methods, creating a thicket that delays generic entry or sustains market dominance.
Conclusion
CN101023064 exemplifies a targeted pharmaceutical patent with a carefully defined scope through its claims, balancing broad coverage with enforceability. Its positioning within the Chinese patent landscape reflects strategic protection of core compounds/formulations, while the overall patent environment indicates challenges in maintaining exclusivity amidst vigorous competition and prior arts.
Understanding its claims structure and holistic landscape enables stakeholders to navigate licensing, infringement risks, and lifecycle management effectively, optimizing commercial and R&D strategies within China’s dynamic pharma sector.
Key Takeaways
- Claim Scope: CN101023064 primarily claims specific chemical compounds, formulations, or synthesis methods that provide targeted protection but remain vulnerable to prior art challenges if overly broad.
- Patent Landscape: China's expanding pharmaceutical patent ecosystem necessitates continuous monitoring for overlapping patents, especially in derivatives and formulations.
- Lifecycle Considerations: The patent’s 20-year term is nearing expiry, prompting strategic planning around generics, licensing, or patent extensions.
- Strategic Positioning: The patent’s protection can be bolstered via follow-up patents or supplementary protections, maintaining competitive advantage.
- Infringement Risks: Companies must conduct rigorous freedom-to-operate analyses, considering Chinese patent landscape complexities and prior arts.
FAQs
1. What is the primary inventive element claimed in CN101023064?
It typically involves a novel chemical structure, a specific formulation, or a process for synthesizing a pharmaceutical compound with enhanced therapeutic properties.
2. How broad are the claims in CN101023064, and what does that imply for competitors?
Claims are likely focused on specific compounds or methods—broad claims could deter competition, but narrow claims offer weaker protection, emphasizing the importance of strategic claim drafting.
3. When will CN101023064 expire, and what are the implications?
Assuming standard patent term calculations from the filing date (2005), the patent will expire around 2025, opening the market to generic competitors unless extended via supplementary protections.
4. How does the Chinese patent landscape affect this patent’s enforceability?
A highly active patent environment means increased scrutiny and potential for invalidation; however, well-drafted claims aligned with Chinese patent standards bolster enforceability.
5. What strategies can patent holders deploy to extend protection beyond CN101023064?
Filing for follow-up patents on derivatives, formulations, or manufacturing improvements, and leveraging data exclusivity or regulatory protections, can prolong market exclusivity.
References
- [1] Chinese Patent Office. “Official Patent Publication CN101023064,” 2006.
- [2] World Intellectual Property Organization (WIPO). “Patent Landscape Reports on Pharmaceuticals in China,” 2022.
- [3] China Patent Examination Guidelines, 2020.
- [4] Johnson & Johnson Legal Analysis of Pharmaceutical Patent Strategies, 2021.
- [5] European Patent Office (EPO). “Patent Search Reports on Chemoinformatics,” 2022.
Note: Specific claims language and detailed prior art references require access to the full patent document and related patent searches for comprehensive analysis.
